Cryolife Inc (NYSE:CRY) Given $13.50 Average Price Target by Brokerages

Cryolife Inc (NYSE:CRY) has earned an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

Analysts have set a 12-month consensus target price of $13.50 for the company and are expecting that the company will post $0.05 EPS for the current quarter, according to Zacks. Zacks has also assigned Cryolife an industry rank of 101 out of 265 based on the ratings given to its competitors.

Shares of Cryolife (NYSE:CRY) opened at 10.78 on Monday. The company has a market capitalization of $306.73 million and a P/E ratio of 99.81. The firm has a 50-day moving average of $10.57 and a 200 day moving average of $10.53. Cryolife has a 1-year low of $9.41 and a 1-year high of $12.29.

Cryolife (NYSE:CRY) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $0.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.09. The firm had revenue of $36.70 million for the quarter, compared to analysts’ expectations of $38.17 million. During the same period in the previous year, the company earned $0.08 EPS. The company’s quarterly revenue was down 1.1% on a year-over-year basis. On average, equities research analysts expect that Cryolife will post $0.09 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, December 18th. Stockholders of record on Friday, December 11th were given a $0.03 dividend. The ex-dividend date of this dividend was Wednesday, December 9th. This represents a $0.12 annualized dividend and a dividend yield of 1.11%.

In other news, CFO David Ashley Lee sold 11,800 shares of the firm’s stock in a transaction dated Monday, November 30th. The shares were sold at an average price of $11.03, for a total value of $130,154.00. Following the completion of the sale, the chief financial officer now directly owns 243,969 shares of the company’s stock, valued at approximately $2,690,978.07. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Several equities research analysts have weighed in on CRY shares. Piper Jaffray reissued an “overweight” rating and set a $15.00 price target on shares of Cryolife in a research report on Thursday, December 24th. Zacks Investment Research raised shares of Cryolife from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Tuesday, December 22nd. Finally, TheStreet raised shares of Cryolife from a “hold” rating to a “buy” rating in a research report on Wednesday, November 25th.

12 Month Chart for NYSE:CRY

CryoLife, Inc. (NYSE:CRY) is a medical device company. The Company is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment includes external revenues from product sales of BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, HeRO Graft, and ProCol. The Preservation Services segment includes external services revenues from the preservation of cardiac and vascular tissues. The Company’s product BioGlue, is a polymer consisting of bovine blood protein and an agent for cross-linking proteins, which was developed for use in cardiac, vascular, pulmonary, and surgical applications. The Company developed BioFoam to seal organs, such as the liver, and for use in cardiovascular surgeries, and provide hemostasis in penetrating wounds and trauma.

Get a free copy of the Zacks research report on Cryolife (CRY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

 

Latest News

Oracle Buying Textura at a Price of $663 Million
Oracle Buying Textura at a Price of $663 Million
AB InBev Offering More Assets of SABMiller in Europe to Win EU Approval
AB InBev Offering More Assets of SABMiller in Europe to Win EU Approval
Verizon Working With Authorities On Sabotage Incidents
Verizon Working With Authorities On Sabotage Incidents
UPS Profit Increases During First Quarter by 10%
UPS Profit Increases During First Quarter by 10%
Consumers Buying Fewer Apple Products, Sales Slump Worldwide
Consumers Buying Fewer Apple Products, Sales Slump Worldwide
Boeing Profit Drops on Lag in Commercial Deliveries
Boeing Profit Drops on Lag in Commercial Deliveries


Leave a Reply

 
© 2006-2017 The Vista Voice. Subscribe